Monolithic Power Systems, Inc. (NASDAQ:MPWR) plans to pay a quarterly dividend of $015 per share on October 15. It said the dividend will capture shareholders of record as of September 30. Meanwhile, the fabless manufacturer of semiconductors said it intends to report its 3Q financial results on October 27. Monolithic Power Systems Inc. (NASDAQ:MPWR) in last trading activity fell -2.61% to close at $34.69. Company weekly performance is -21.27% while its quarterly performance stands at -15.84%. Monolithic Power Systems Inc. (NASDAQ:MPWR) is -27.85% away from its 52 week high.ArcelorMittal SA (NYSE:MT) last announced its earnings results on Friday, August 1st. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.17. The company had revenue of $10.70 billion for the quarter, compared to the consensus estimate of $20.42 billion. During the same quarter in the previous year, the company posted ($0.44) earnings per share. The company’s revenue for the quarter was down 47.0% on a year-over-year basis. Analysts expect that ArcelorMittal SA will post $0.39 EPS for the current fiscal year. On last trading day ArcelorMittal SA (ADR) (NYSE:MT) increased 2.66% to close at $12.34. Its volatility for the week is 3.17% while volatility for the month is 2.24%. MT's sales growth for past 5 years was -7.40% and its EPS growth for past 5 years was -17.30%. ArcelorMittal SA (ADR) (NYSE:MT) monthly performance is -13.65%.Amgen Inc. (NASDAQ:AMGN) on Oct. 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow.1 As part of the acceptance, the FDA granted blinatumomab priority review with a Prescription Drug User Fee Act (PDUFA) action date of May 19, 2015. On last trading day Amgen Inc. (NASDAQ:AMGN) fell -2.79% to close at $133.56. Its volatility for the week is 2.65% while volatility for the month is 2.01%. AMGN's sales growth for past 5 years was 4.50% and its EPS growth for past 5 years was 12.00%. Amgen Inc. (NASDAQ:AMGN) monthly performance is -3.14%.Oncolytics Biotech Inc. (NASDAQ:ONCY) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Wednesday, 01 October 2014. Oncolytics Biotech Inc. (NASDAQ:ONCY) has institutional ownership stands at 2.50%. In last trading activity company's stock closed at $0.49.Albany Molecular Research Inc. (NASDAQ:AMRI) major shareholder Stuart M. Cable unloaded 30,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $21.61, for a total transaction of $648,300.00. On Monday shares of Albany Molecular Research Inc. (NASDAQ:AMRI) closed at $20.95. Company's sales growth for last 5 years was 1.50%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
